What Is Market Access in Pharma and Why Launches Fail Without It

A drug gets regulatory approval. The clinical data is strong. The medical community is excited. Twelve months later, the product has reached less than 20% of the eligible patient population. Revenue is 40% below forecast. The commercial team is frustrated. Investors are concerned.

What happened? The drug works. But patients cannot get it. Payers restricted formulary access. The price was too high for key markets. HTA bodies in Europe gave unfavorable recommendations. The evidence package did not address what payers actually needed to see.

This is a market access failure. Market access is the discipline that determines whether a clinically successful drug actually reaches the patients who need it – at a price the system will pay. This article explains what market access covers, why it matters more now than ever, and where launches fail without it.

The Problem: Clinical Success Does Not Guarantee Commercial Success

The gap between regulatory approval and patient access is growing wider. Several structural factors explain this.

Payer scrutiny is increasing. HTA bodies (NICE in the UK, G-BA in Germany, HAS in France) apply stricter evidentiary standards.

Pricing pressure is global. International reference pricing means the price in one country affects what you can charge elsewhere. The IRA introduces Medicare price negotiation.

Formulary restrictions are tightening. Even with approval, step therapy, prior authorization, or restricted placement reduces patient reach.

According to IQVIA Institute, approximately 50% of pharmaceutical launches in 2020-2024 underperformed commercial forecasts, with market access barriers as the primary factor.

The Insight: Market Access Is Not Just Pricing

The most common misconception is that market access is primarily about pricing. It encompasses everything that determines whether an approved drug reaches patients at a sustainable price.

The real insight: Companies that consistently achieve strong market access start planning 3-5 years before launch – during Phase 2. Companies that begin after approval are already behind.

Decision Intelligence: Why Launches Fail – Five Patterns

The Solution: Market Access Planning Timeline

The Value: What Good Market Access Delivers

Example: Two Launches, Same Indication, Different Outcomes

Two companies launch in the same rare disease indication within 6 months.

Company A begins market access in Phase 2. They conduct payer advisory boards, learn that payers want functional outcome data, add a secondary endpoint, engage NICE early scientific advice, and set global pricing 24 months pre-launch. Result: positive NICE recommendation, broad access, Year 1 revenue exceeds forecast by 15%.

Company B focuses on clinical development. Market access starts 12 months pre-approval. Their data lacks functional outcomes. They submit to NICE without early advice. Result: restricted recommendation, US price undercut by reference pricing. Year 1 revenue is 35% below forecast.

The clinical data was comparable. The market access planning was not.

Conclusion

Market access bridges regulatory approval and patient access. It encompasses health economics, pricing, HTA submissions, payer engagement, and patient support.

The fundamental lesson is timing. Companies that start in Phase 2 consistently outperform those beginning after approval. If you are new to market access, focus on the five failure patterns and the planning timeline. These two frameworks will guide where to invest your attention.

Go deeper on market access components. Explore how HTA systems compare across markets and how international reference pricing shapes global strategy.

Frequently Asked Questions

The Market Access Planning Timeline: When to Start and What to Prepare

Market access planning should begin at Phase 2 proof-of-concept, not at NDA/BLA submission. At Phase 2, the market access team should define the target product profile with reimbursement criteria in mind – what evidence payers will require for a positive decision. At Phase 2b/3 initiation, health economic modelling begins: cost-effectiveness models, budget impact models, and patient-reported outcome instrument selection. At Phase 3, engage patient advocacy groups for patient-reported outcome data and key payer scientific advice to confirm the evidence package is aligned with reimbursement expectations. At NDA/BLA submission, the market access dossier should be ready to submit to major HTA bodies simultaneously.

The Market Access Team: Who You Need and When to Hire Them

Market access strategy should be present in your organisation from Phase 2 initiation – but the team size scales with development stage. At Phase 2 entry: you need one market access director or VP with payer strategy experience, typically supported by a health economics consultancy for the initial models. At Phase 3 initiation: expand to a 3-5 person team including health economics modelling capability, country-specific market access leads for major markets, and a real-world evidence strategy lead. At NDA/BLA submission: the full market access team should include regional directors for US, EU, Japan, and emerging markets, payer insights leads, and outcomes research capabilities. Companies that hire market access leadership before Phase 3 consistently achieve faster time-to-reimbursement.

More Questions Answered

Building the Health Economic Model: What You Need Before HTA Submission

The health economic model is the centrepiece of most HTA submissions. Building a credible model requires five inputs: clinical efficacy data (preferably head-to-head versus the comparator, not just placebo-controlled data), quality-of-life data (EQ-5D-3L or EQ-5D-5L utility scores collected in the Phase 3 trial), unit cost data (hospitalisation, treatment, productivity costs from country-specific databases), the appropriate comparator (defined by local clinical practice guidelines, not your preferred competitor), and a transparency-ready model architecture (reviewable by HTA analysts, with one-way and probabilistic sensitivity analyses). Models that fail HTA review most commonly fail on comparator selection or insufficient sensitivity analysis demonstrating that results are robust across assumptions.